Among patients with C/EBPα mutations, 91% were in the CN-AML molecular high-risk group (FLT3-ITD-positive and/or NPM1-wild-type), although they seemed to be associated with a good prognosis in AML with an intermediate-risk karyotype [80]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.